What a hip osteochondral defect actually is

A hip osteochondral defect is a divot in the joint surface that goes deeper than most people expect. Rather than affecting just the smooth cartilage lining the femoral head, it punches through into the bone beneath — leaving a crater where both tissue layers are missing or damaged. That distinction matters clinically: a repair that addresses cartilage alone cannot restore the structural foundation the joint needs.

Several conditions can produce this kind of combined lesion. Trauma is one direct cause; others develop more gradually through femoroacetabular impingement (FAI), avascular necrosis (where the bone loses its blood supply and collapses), developmental hip dysplasia, or Legg-Calvé-Perthes disease. These defects are rare, and because early symptoms can be subtle and imaging findings easy to miss, diagnosis is often delayed — particularly in younger patients who might otherwise be assumed to have a straightforward soft-tissue problem.

In published surgical series, the typical patient is in their early twenties. That age profile is central to how clinicians frame the treatment goal: not replacement, but preservation. The aim is to restore a durable joint surface in a hip that should last another five or six decades — buying time, function, and ideally a normal life before any question of total hip arthroplasty even arises.

Why defect size is the deciding factor

The choice between OATS and OCA comes down, above all else, to one measurement: how large the defect is.

Autograft transfer (OATS) suits small, contained lesions — typically no more than 2 cm² — where a plug of bone and cartilage of sufficient diameter can be harvested from the non-weight-bearing zone of the femoral head without causing unacceptable structural harm. Beyond that size threshold, there is simply no autograft plug large enough to fill the defect adequately, and that is where fresh osteochondral allograft (OCA) becomes the appropriate option.

This distinction is borne out by the only published head-to-head comparison of the two approaches in the femoral head: a 2025 multicenter study of 27 patients. Autograft recipients had lesions averaging 1.6 × 1.0 cm; allograft recipients had lesions averaging 2.8 × 2.1 cm. Despite that substantial difference in defect area, functional outcomes at follow-up were essentially identical — modified Harris Hip Scores of 87.6 for the autograft group and 86.7 for the allograft group, with Hip Outcome Score–ADL values within a fraction of each other.

Equivalent scores do not mean the two procedures are interchangeable. They mean each technique, when applied to the defect size it is designed for, can produce a comparable functional result. The selection criterion is not surgeon preference — it is anatomy.

OATS for smaller hip defects: what autograft transfer involves

Performing OATS on the femoral head follows the same core principle as autograft transfer in other joints: a cylindrical core of bone and cartilage — the plug — is taken from a low-stress zone and pressed into the damaged area, restoring the joint surface in a single operation.

What makes the hip version technically demanding is the anatomy. The tight fit between the femoral head and the acetabulum means the surgeon cannot insert a plug at an angle; it must go in truly perpendicular to the articular surface to seat properly and survive loading. Achieving that angle typically requires surgical hip dislocation (SHD) — a carefully controlled procedure in which the hip is dislocated under direct vision, the full surface of the femoral head is exposed, and the plug is placed precisely. This is not routine arthroscopy, and OATS for the hip is carried out only at specialist hip preservation centres.

A clinically important development concerns the donor site. Older autograft technique required a separate incision — usually at the knee — to harvest the plug. Surgeons can now take it from the non-weight-bearing zone of the same femoral head being operated on, during the same procedure. This same-femoral-head harvest approach eliminates a second wound entirely and avoids the structural weakening that comes from harvesting multiple holes at a remote site — removing one of the concerns that historically made patients and surgeons cautious about autograft in the hip.

In the 2025 multicenter study, the eight patients who received autograft achieved a mean modified Harris Hip Score of approximately 87, and none required conversion to total hip arthroplasty during follow-up. For a young patient weighing the options, that is a meaningful early signal — one to hold in proportion given the small numbers, but a genuinely encouraging one.

OCA for larger defects: what fresh allograft transplantation involves

Fresh osteochondral allograft (OCA) replaces the entire damaged zone with a matched plug of bone and cartilage from a donor femoral head, sized and contoured to fit the specific defect. Because the graft incorporates full-thickness bone as well as viable articular cartilage, it can restore areas that no autograft plug — however carefully harvested — could adequately cover.

The surgery is performed via surgical hip dislocation, the same specialist access required for OATS, and for the same anatomical reason: only by fully exposing the femoral head can the surgeon seat the plug truly perpendicular to the joint surface. OCA is therefore carried out at the same hip preservation centres that perform autograft transfer.

A factor patients rarely know to raise — but which the evidence suggests is as clinically decisive as the operation itself — is how the allograft is stored before it is implanted. In a 33-patient series examining graft preservation methods, allografts stored under the Missouri Osteochondral Preservation System (MOPS) protocol achieved 100% success compared with 50% for those held under standard preservation conditions, an odds ratio of 47 (p=0.001). Graft viability is not a constant: it depends directly on the storage protocol a centre uses, and asking about this when choosing where to be treated is entirely reasonable.

On functional outcomes, published single-centre series report meaningful gains: modified Harris Hip Score rising from approximately 58–62 before surgery to around 84 afterwards, with iHOT-12 improving from roughly 35 to 78; between 67% and 84% of patients reached the minimum clinically important difference on these measures. These are genuine improvements — though OCA restores a functioning joint surface rather than replicating the properties of undamaged native cartilage.

Survivorship data and the risk of progressing to hip replacement

Survivorship figures for femoral head OCA tell a clear, if sobering, story. The longest published series — 22 patients followed to nine years — shows graft survival at 86% at two years, 79% at five years, and 67% at nine years: a meaningful decline that patients should understand before committing to the procedure.

A systematic review of 5,952 osteochondral allograft patients reports more favourable figures — 94%, 87.9%, and 80% at two, five, and ten years respectively. Because approximately 89% of that dataset comes from knee procedures, those numbers serve as a general benchmark rather than a hip-specific prediction.

Conversion to total hip arthroplasty runs at 14–25% in published hip OCA series within approximately four years. The 2025 multicenter study found 21.1% of OCA recipients had progressed to hip replacement at a mean of 1.9 years, against 0% of autograft patients. That contrast deserves context: the autograft group started with substantially smaller defects — averaging 1.6×1.0 cm versus 2.8×2.1 cm — so the 0% conversion figure most likely reflects a more favourable starting point rather than any intrinsic superiority of the autograft technique.

When avascular necrosis (bone death caused by disrupted blood supply) is the underlying cause of the defect, outcomes after both OCA and autograft are consistently worse than for other indications such as dysplasia or post-traumatic injury — making aetiology an important part of any individual risk discussion.

All these figures come from small, retrospective case series, most with follow-up under five years and none from randomised trials. They represent the best available evidence in a field where patient numbers at any single centre remain low.

Who is likely to be a candidate and what assessment involves

Suitable candidates share a consistent profile across published series: most are younger adults — typically under 50 — with a focal, contained lesion confined to the femoral head, well-preserved cartilage in the surrounding joint, and no widespread degenerative change. Defect size, the underlying cause, and overall bone stock are all considered before any surgical plan is formed. Dysplasia and post-traumatic injury carry a more favourable prognosis than osteonecrosis, which is associated with worse outcomes after both OATS and OCA — making aetiology a substantive part of individual risk assessment, not a formality.

Imaging before either procedure typically includes MRI to characterise defect dimensions, cartilage integrity, and bone quality, with CT sometimes added to assess subchondral bone stock in greater detail. Findings inform a conversation between patient and surgeon rather than replacing it; no imaging result is itself a decision.

Centre expertise is a genuine, non-trivial differentiator. Both procedures require a unit where surgical hip dislocation is performed as a routine part of the caseload — not occasionally. Patients are well within their rights to ask how many femoral head osteochondral transplantations a centre has carried out, how grafts are stored before implantation, and whether alignment or labral issues will be addressed at the same sitting. These are clinical questions, not awkward ones.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without GP referral for hip assessment, including those at the point of exploring hip preservation options.

1. [1] FP5.7 Clinical Outcomes following Osteochondral Allograft Transplantation of the Femoral Head via Surgical Hip Dislocation. (2025). https://doi.org/10.1093/jhps/hnaf011.045 https://doi.org/10.1093/jhps/hnaf011.045
2. [2] Osteochondral Allograft and Autograft Transplant for Femoral Head Defects: A Multicenter Study. (2025). https://doi.org/10.1177/03635465251338062 https://doi.org/10.1177/03635465251338062
3. [3] FP5.8 Osteochondral Allograft and Autograft Transplantation for Femoral Head Defects: A Multicenter Study with a Mean 5-Year Follow-Up. (2025). https://doi.org/10.1093/jhps/hnaf011.046 https://doi.org/10.1093/jhps/hnaf011.046
4. [4] Osteochondral Allograft Transplantation of the Femoral Head via Surgical Hip Dislocation: Survivorship and Patient Reported Outcome Measures at Minimum 2-Year Follow-Up. (2025). https://doi.org/10.1177/23259671251385115 https://doi.org/10.1177/23259671251385115
5. [5] Modified osteochondral autograft transplantation for steroid-induced osteonecrosis of femoral head in idiopathic thrombocytopenic purpura: a case report and literature. (2024). https://doi.org/10.1186/s12891-023-07108-z https://doi.org/10.1186/s12891-023-07108-z
6. [6] Osteochondral autograft transplantation of the femoral head in sequelae of developmental dysplasia of hip: A case report and review of the literature. (2020). https://doi.org/10.5606/ehc.2020.75135 https://doi.org/10.5606/ehc.2020.75135
7. [7] Outcomes associated with hip preservation using osteochondral allograft transplants and acetabular labrum reconstruction. (2024). https://doi.org/10.1177/11207000241288445 https://doi.org/10.1177/11207000241288445
8. [8] A Technique for Arthroscopic Osteochondral Autograft Transplantation of the Hip. (2019). https://doi.org/10.1016/j.eats.2018.09.008 https://doi.org/10.1016/j.eats.2018.09.008